Guerbet Announces AHRA Charitable Contribution

26.07.2018 16:43

Guerbet Announces AHRA Charitable Contribution to Support Next Generation Leaders in Medical Imaging

PRINCETON, N.J., July 24, 2018 -- Guerbet LLC USA, the U.S. affiliate of the global specialist in contrast product and solutions for medical imaging, announced today a contribution of $50,000 to the Association for Medical Imaging Management (AHRA) “Defining Our Future” campaign, an initiative to support the education, development, and empowerment of new and future medical imaging professionals.

“Guerbet is honored to support AHRA’s ambitious initiative to shape the future of medical imaging and quality care,” said Massimo Carrera, Guerbet Vice President for North America. “As a global leader in medical imaging, we are excited to partner with AHRA to help equip members with the tools they need to create positive change in medical imaging management space.”

The contribution echoes Guerbet’s growing partnership with AHRA to deliver the highest quality of care to patients with pioneering technologies in diagnostic and interventional imaging. For many years Guerbet has led industry advances with AHRA’s support, including the L-F Hydra Vision™ Digital Imaging System, a real-time digital X-ray imaging device in urological imaging; the OptiStar® Elite injector for improved MRI contrast delivery; Contrast & Care data analytics to enhance imaging center capabilities; and the Imalogix ™ dose management system to increase patient safety in interventional imaging procedures.

To learn more about AHRA’s “Defining Our Future” campaign, visit

Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, in Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €807 million in revenue in 2017. For more information about Guerbet, please visit

Guerbet US
Ted Deutsch
US (609) 683-0700